386 related articles for article (PubMed ID: 37313406)
1. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
[TBL] [Abstract][Full Text] [Related]
2. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
[TBL] [Abstract][Full Text] [Related]
3. Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: Systematic review and meta-analysis of real-world evidence.
Xie W; Xiao S; Li X; Huang J; Li G; Zhang Z
Eur J Intern Med; 2023 Sep; 115():88-95. PubMed ID: 37263805
[TBL] [Abstract][Full Text] [Related]
4. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors.
Yan H; Tang M; Zhu W; Yang Y
Clin Exp Nephrol; 2023 Jul; 27(7):603-612. PubMed ID: 37014535
[TBL] [Abstract][Full Text] [Related]
6. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
Whitlock R; Leon SJ; Manacsa H; Askin N; Rigatto C; Fatoba ST; Farag YMK; Tangri N
Nephrol Dial Transplant; 2023 Oct; 38(11):2503-2516. PubMed ID: 37309038
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-Converting Enzyme Inhibitor/Receptor Blocker, Diuretic, or Nonsteroidal Anti-inflammatory Drug Use After Major Surgery and Acute Kidney Injury: A Case-Control Study.
Roberts DJ; Smith SA; Tan Z; Dixon E; Datta I; Devrome A; Hemmelgarn BR; Tonelli M; Pannu N; James MT
J Surg Res; 2021 Jul; 263():34-43. PubMed ID: 33631376
[TBL] [Abstract][Full Text] [Related]
8. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
[TBL] [Abstract][Full Text] [Related]
9. Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study.
Gérard AO; Barbosa S; Parassol N; Andreani M; Merino D; Cremoni M; Laurain A; Pinel S; Bourneau-Martin D; Rocher F; Esnault VLM; Borchiellini D; Sicard A; Drici MD;
Clin Kidney J; 2022 Oct; 15(10):1881-1887. PubMed ID: 36158153
[TBL] [Abstract][Full Text] [Related]
10. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
[No Abstract] [Full Text] [Related]
11. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
12. Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.
Liu F; Wang Z; Li X; Zhang Z; Yang Y; Chen J; Chen D; Wu L; Liu X; Han S; Wang F; Wahafu W; Gao Y; Ren S; Xing N; Cai G; Chen X
Cancer Commun (Lond); 2023 Feb; 43(2):214-224. PubMed ID: 36528491
[TBL] [Abstract][Full Text] [Related]
13. Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.
Liu K; Qin Z; Ge Y; Bian A; Xu X; Wu B; Xing C; Mao H
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5061-5070. PubMed ID: 36326913
[TBL] [Abstract][Full Text] [Related]
14. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
[TBL] [Abstract][Full Text] [Related]
15. Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review.
Li H; Zhang L; Yang F; Zhao R; Li X; Li H
Front Immunol; 2023; 14():1218386. PubMed ID: 37841249
[TBL] [Abstract][Full Text] [Related]
16. Drug discontinuation before contrast procedures and the effect on acute kidney injury and other clinical outcomes: a systematic review protocol.
Hiremath S; Kayibanda JF; Chow BJW; Fergusson D; Knoll GA; Shabana W; Lahey B; McBride O; Davis A; Akbari A
Syst Rev; 2018 Feb; 7(1):34. PubMed ID: 29467030
[TBL] [Abstract][Full Text] [Related]
17. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors.
Guven DC; Ozbek DA; Sahin TK; Kavgaci G; Aksun MS; Erul E; Yildirim HC; Chalabiyev E; Cebroyilov C; Yildirim T; Dizdar O; Aksoy S; Yalcin S; Kilickap S; Erman M; Arici M
Anticancer Drugs; 2023 Jul; 34(6):783-790. PubMed ID: 36729111
[TBL] [Abstract][Full Text] [Related]
18. Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Shen J; Hou H; Liang B; Guo X; Chen L; Yang Y; Wang Y
Front Immunol; 2023; 14():1155104. PubMed ID: 37153578
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
Front Oncol; 2022; 12():934093. PubMed ID: 35912183
[TBL] [Abstract][Full Text] [Related]
20. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
